Get started
Work

Baseline Characteristics of Participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial

Year: 2020
Type: article
Abstract: Hyperhomocysteinemia may be a modifiable risk factor for the prevention of arteriosclerotic outcomes in chronic kidney disease (CKD). Few clinical trials of homocysteine lowering have been conducted in persons with CKD prior to reaching end-stage renal disease. Kidney transplant recipients are considered individuals with CKD.
DOI: 10.17615/bhmg-c686
Authors: Bostom, Andrew G., Levey, Andrew S., Carpenter, Myra A., Kusek, John W., Jacques, Paul F., Pfeffer, Marc A., Hunsicker, Lawrence, Selhub, Jacob, Mercier, Renee Y., McKenney, Joyce L.
Language: English
Subfield: Rheumatology
Field: Medicine
Open Access status: green
OpenAlex ID: W4298328642
FWCI:
Cites:
Cited by:
Related to: 10